Form 10-Q · Quarterly report

Moderna 10-Q, filed Nov 6, 2026

Filed
CIK
0001682852
Accession no.
0001682852-26-000197
AI-generated summary

Summary

Moderna reported third-quarter 2026 total revenue of $1.31 billion and net income of $162 million, swinging from a $200 million net loss a year earlier, while its nine-month net loss was $1.96 billion. The company issued $3.0 billion in convertible notes during the first nine months of 2026 and said it had five approved products as of September 30, 2026.

Key points

  • Third-quarter 2026 total revenue was $1.31 billion, up from $1.02 billion in the same quarter of 2025, including $1.27 billion of net product sales.
  • Moderna posted net income of $162 million, or $0.38 per diluted share, for the quarter, versus a net loss of $200 million a year earlier; the nine-month net loss was $1.96 billion.
  • The company issued $3.0 billion of convertible notes in the nine months ended September 30, 2026, and paid $329 million for related capped calls.
  • Moderna listed five approved products as of September 30, 2026, and said it is jointly developing intismeran autogene (mRNA-4157) with Merck in nine Phase 2 and Phase 3 trials across multiple tumor types.

Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.

From the filing

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 33 Item 3. Quantitative and Qualitative Disclosures about Market Risk 43 Item 4. Controls and Procedures 43 PART II. Item 1. Legal Proceedings 44 Item 1A. Risk Factors 45 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 47 Item 5. Other Information 47 Item 6. Exhibits 48 SIGNATURES 49 Table of Contents Item 1. Financial Statements MODERNA, INC. …

An excerpt of the text as filed with the SEC, cut for length.

Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.

Follow Moderna in Readster

Add Moderna to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.

No credit card. When the trial ends, you move to Readster Free unless you subscribe.